Rezetecán
Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) [1][2].
Product Specifications
Product Name Alternative
SHR9265
UNSPSC
12352005
Target
ADC Payload; Topoisomerase
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rezetec-n.html
Purity
99.60
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)[C@@H](N)CSC(C1)C(N(CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCO[C@H](C3CC3)C(N[C@H]4CCC5=C6C4=C(CN7C(C(COC([C@@]8(CC)O)=O)=C8C=C79)=O)C9=NC6=CC(F)=C5C)=O)=O)=O)=O)=O)=O)C1=O)=O
Molecular Formula
C58H67FN10O15S
Molecular Weight
1195.27
References & Citations
[1]WHO Drug Information, Vol. 36, No. 2, 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.|[2]Loganzo F, et al. Mechanisms of resistance to antibody–drug conjugates[J]. Molecular cancer therapeutics, 2016, 15 (12) : 2825-2834.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TMPH-00320-01 5 µg
Snaclec rhodocytin subunit alpha Protein, Calloselasma rhodostoma, Recombinant (His)
Sign In for Pricing
View Details TMPH-00320-02 10 µg
Snaclec rhodocytin subunit alpha Protein, Calloselasma rhodostoma, Recombinant (His)
Sign In for Pricing
View Details TMPH-00320-03 20 µg
Snaclec rhodocytin subunit alpha Protein, Calloselasma rhodostoma, Recombinant (His)
Sign In for Pricing
View Details TMPH-00320-04 50 µg
Snaclec rhodocytin subunit alpha Protein, Calloselasma rhodostoma, Recombinant (His)
Sign In for Pricing
View Details